Role of imaging in diagnosis, staging and follow-up of lung cancer

Wever, Walter De; Verschakelen, Johny; Coolen, Johan

doi:10.1097/mcp.0000000000000066

Cited by 18 publications

(11 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Early detection of lung cancer is important because the only curative therapy today is surgical resection of early-stage tumours [20]. Crucially, for patients whose lung cancers are detected at stage 1 the outcome is substantially better than average.…”

Section: Discussionmentioning

confidence: 99%

A quantitative immunoassay for lung cancer biomarker CIZ1b in patient plasma

Coverley

Higgins

West

et al. 2017

Clinical Biochemistry

View full text Add to dashboard Cite

ObjectivesNon-invasive tests for early detection of lung cancer are an important unmet clinical need. CIZ1b plasma biomarker can discriminate stage 1 lung cancer from within high-risk groups with clinically useful accuracy, with ROC AUCs in excess of 0.9 for two independent retrospective cohorts, and could therefore meet this need. Our aim was to characterise the native state of the biomarker and develop a quantitative immunoassay.Design and methodsSelective denaturation, preparative electrophoresis and mass spectrometry of human plasma were used to characterise the biomarker and interaction partners. A sandwich ELISA was generated, and specificity for CIZ1b biomarker tested on lung cancer patient plasma.ResultsCIZ1b biomarker is a denaturation-resistant complex between a C-terminal fragment of CIZ1 bearing the CIZ1b epitope specified by alternative splicing of exon14, and fibrinogen alpha chain. Reconstitution of the biomarker epitope with purified fibrinogen and CIZ1b, but not CIZ1a (non-alternatively spliced exon 14) confirmed the specificity of the results. The endogenous complex is highly stable in lung cancer plasma and can be quantified by pairing of a CIZ1b exon-junction specific antibody with detection of fibrinogen. Application of this sandwich ELISA to a prospectively collected development set of plasmas reveals the same level of accuracy as the western blot used to validate the discriminatory capability of the biomarker.ConclusionsUnexpected and unusual molecular structure of CIZ1b in native plasma has complicated immunoassay design, and delayed translation of this promising biomarker. However, CIZ1b can now be measured using a high-throughput, hospital-friendly sandwich ELISA format, overcoming an important barrier to further clinical development and application of this blood test for early stage lung cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

A quantitative immunoassay for lung cancer biomarker CIZ1b in patient plasma

Coverley

Higgins

West

et al. 2017

Clinical Biochemistry

View full text Add to dashboard Cite

show abstract

“…18 F-FDG PET/CT is widely used as imaging standard of reference for bronchial carcinoma and shows a high sensitivity (around 96 %) for the detection of malignant lung nodules. Specifi city remains lower (about 80 %), as false-positive results can occur in infectious or granulomatous disease of the lung [ 30 ]. Also in lymphoma, an entity with many 18 F-FDG-avid subtypes, 18 F-FDG PET/CT is now the recommended imaging standard of reference for staging and restaging [ 31 ].…”

Section: Extracervical Cupmentioning

confidence: 98%

The Radiologist’s Approach to CUP

Kazmierczak

Rominger

Cyran

2016

Cancer of Unknown Primary

View full text Add to dashboard Cite

In 2-4 % of patients with histologically proven cancer, the primary tumor cannot be localized, even by use of modern diagnostic methods. This situation is clinically described as cancer of unknown primary (CUP) [ 1 , 2 ] and has a frequency similar to pancreatic cancer, renal cell carcinoma, or leukemia [ 3 ]. Even after extensive diagnostic workup using state-of-the-art methods, less than 20 % of primary tumors are localized antemortem, compared to almost 80 % of primary tumors identifi ed in postmortem autopsy series [ 4 ].CUP tumors are adenocarcinomas in 40-60 %, undifferentiated carcinomas in 15-20 %, squamous cell carcinomas in 5-8 %, and neuroendocrine tumors in 3-5 %; 1-3 % of all CUP belong to other entities [ 5 ]. Most frequently, primary tumors are localized in the lung (20-35 %) and the pancreas (15-20 %), followed by other gastrointestinal and gynecological malignancies. Median survival in this heterogenic group of cancer patients is only 3-11 months [ 6 ]. Imaging is essential in all four steps of the diagnostic and therapeutic management of CUP patients [ 7 ]: localization of the primary tumor, identifi cation of all manifestations, identifi cation of potentially treatable tumors (i.e., breast cancer, prostate carcinoma, lymphoma, etc.), and characterization of the clinicopathological entity and stratifi cation into subsets with favorable prognosis (approximately 20 %) with differentiated and/or chemosensitive tumors for which specifi c treatment options are available and, on

show abstract

“…3,5 O carcinoma escamoso apresenta lesões centrais em 65% dos casos, podendo obstruir o brônquio e evoluir com atelectasia, consolidação (pneumonia obstrutiva), cavitação (10 a 20%) e abscessos. 2,6 No adenocarcinoma encontra-se frequentemente (60% a 70% das vezes) na forma de massa periférica. A cavitação é rara.…”

Section: Imagens No Câncer De Pulmãounclassified

“…Quando a imagem é nodular, a borda costuma ser mal definida. 2,6 O carcinoma indiferenciado de grandes células apresenta-se como lesões periféricas em 60% dos casos e costuma ser maior do que 4 cm. A cavitação é rara.…”

Section: Imagens No Câncer De Pulmãounclassified

See 1 more Smart Citation

Câncer de pulmão: atualização da terapêutica cirúrgica

Saito

Rufino

Costa

et al. 2015

Revista Hospital Universitário Pedro Ernesto

View full text Add to dashboard Cite

O câncer de pulmão é uma doença agressiva e seu diagnóstico precoce direciona o tratamento para uma maior chance de cura. Dados gerais da literatura apontam que uma minoria de pacientes (cerca de 30%), portadores de carcinoma não pequenas células, limitadas ao pulmão, beneficiam-se do tratamento cirúrgico curativo. Desta forma, todo esforço para um diagnóstico precoce deve ser realizado. O objetivo deste artigo de atualização é abordar o tema proposto de uma forma geral, ressaltando as informações mais relevantes para profissionais da área de saúde. Exames cada vez mais sofisticados podem ser utilizados na prática médica, assim como técnicas cirúrgicas mais evoluídas e inovações de quimioterapia/radioterapia complementam o avanço para uma maior sobrevida.

show abstract

Role of imaging in diagnosis, staging and follow-up of lung cancer

Cited by 18 publications

References 53 publications

A quantitative immunoassay for lung cancer biomarker CIZ1b in patient plasma

A quantitative immunoassay for lung cancer biomarker CIZ1b in patient plasma

The Radiologist’s Approach to CUP

Câncer de pulmão: atualização da terapêutica cirúrgica

Contact Info

Product

Resources

About